Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : RÉSISTANCE SOUS TRAITEMENT COMBINATOIRE DANS LE CANCER DU SEIN ER+ ET ER-. Hor26/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
RÉSISTANCE SOUS TRAITEMENT COMBINATOIRE DANS LE CANCER DU SEIN ER+ ET ER-.
Breast Cancer (BC) is the first cause of cancer-related death in women worldwide. Breast cancer is classified into well-recognized molecular subtypes. Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification. Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to some degree arbitrary. This proposal seeks to develop new approaches and identify mechanisms of treatment resistance at systems level, exploring how the effectiveness of specific targeted therapies applied in different clinical trials is affected by patient- and tumor-specific conditions. For this purpose, the project will gather and integrate longitudinal multidimensional data from ongoing clinical trials and newly generated --omics using systems approaches, which combine sub-cellular/cellular and/or organ level in-silico models and network analysis to build computational frameworks able to discover molecular signatures of resistance and predict patient response to combinatorial therapies. We aim to identify the physiological characteristics of non-responders vs. responders from existing and newly generated multi-omic data and biological samples from in-vivo and ex-vivo clinical studies of specific subtypes of BC patients treated with combination therapy. This new knowledge will be used to investigate the curative potential of new personalized drugs combinations. The overreaching goal is to develop computer “xenograft model” as a cost-efficient and better alternative in terms of ethics, availability to everyone, and animal use. The framework will include optimization algorithms to identify combinations of approved drugs with a high probability to work on individual or thin strata of patients. The project is endowed with a “legal” framework addressing ethical aspects
| Commissariat a L Energie Atomique et aux Energies Alternatives | 389 013 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 400 000 € |
| Fundacion de Investigacion del Cancer de La Universidad de Salamanca | 357 896 € |
| HELSINGIN YLIOPISTO | 946 444 € |
| Hospital Clinic de Barcelona | 0,00 € |
| INSTITUT FUR FRAUENGESUNDHEIT GmbH | 141 294 € |
| Karolinska Institutet | 424 781 € |
| NANTOMICS LLC | 0,00 € |
| Norges Teknisk-Naturvitenskapelige Universitet Ntnu | 0,00 € |
| Oslo Universitetssykehus HF | 935 625 € |
| REICHMAN UNIVERSITY | 371 875 € |
| RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 8 000,00 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 273 000 € |
| Universitat de Barcelona | 108 442 € |
| UNIVERSITATSKLINIKUM ERLANGEN | 245 713 € |
| Universitetet I Oslo | 933 544 € |
| VIB VZW | 464 375 € |
https://cordis.europa.eu/project/id/847912
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.